Yayınlar & Eserler

Yayın Ağı
Makaleler 5
Tümü (5)
SCI-E, SSCI, AHCI (5)
SCI-E, SSCI, AHCI, ESCI (5)
Scopus (5)

1. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

Kıkılı C. İ., Araz M., ÜRÜN Y., BAŞARAN M., Şener N., Yazar A., et al.
Clinical Genitourinary Cancer , cilt.24, sa.5, 2026 (SCI-Expanded, Scopus)

2. Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure

Kemik F., Şahin T., ÖZÇELİK H., Sezer A., BAŞARAN G., Açıkel Yüksel S., et al.
Breast , cilt.87, 2026 (SCI-Expanded, Scopus)

3. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

Sünger E., Muğlu H., Yücel M. H., Engin Delipoyraz E., Mıldanoğlu M. M., Özçelik H., et al.
Journal of clinical medicine , cilt.15, sa.8, 2026 (SCI-Expanded, Scopus)

4. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

Mıldanoğlu M. M., Kemik F., Eryaşar M., ÖZÇELİK H., SÜNGER E., Yücel M. H., et al.
Pharmaceuticals (Basel, Switzerland) , cilt.19, sa.4, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

5. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

Mildanoglu M. M., Yucel M. H., Engin Delipoyraz E., SÜNGER E., ÖZÇELİK H., FİDAN S., et al.
Journal of clinical medicine , cilt.15, sa.6, 2026 (SCI-Expanded, Scopus)
Metrikler

Yayın

5

Yayın (WoS)

5

Yayın (Scopus)

5
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER